Thursday, April 18, 2013
The Institute of Cancer Research and Cancer Research Technology Ltd. are collaborating with Janssen Research & Development
of Johnson & Johnson to modulate the unfolded protein response in multiple
myeloma. Although no particulars have been disclosed by the partners, previous
results from the U.K. team have suggested the kinase domain of IRE1 as
a potential target in the pathway.
Building up stress
The ICR-CRT-Janssen partnership will focus
on an undisclosed target in a part of the stress response pathway called the unfolded
protein response (UPR).
Translocation SET up
The UPR is not the only emerging pathway
in MM being tackled by ICR and CRT. The Janssen deal comes on the heels of an
ICR-CRT partnership with Astex Pharmaceuticals Inc. around an epigenetic target-the histone methyltransferase Wolf-Hirschhorn syndrome candidate 1 (WHSC1; MMSET)-that is implicated in MM. About 20% of patients with MM
have a tumor translocation that deregulates MMSET.
Kotz, J. SciBX 6(15); doi:10.1038/scibx.2013.354
Published online April 18, 2013
1. Ali, M.M.U. et al.
EMBO J. 30, 894-905 (2011)
2. Kotz, J. SciBX 4(10);
3. Asangani, I.A. et
al. Mol. Cell 49, 80-93 (2013)
AND INSTITUTIONS MENTIONED
Astex Pharmaceuticals Inc. (NASDAQ:ASTX), Dublin, Calif.
Cancer Research Technology Ltd., London, U.K.
Cancer Research UK, London, U.K.
Celgene Corp. (NASDAQ:CELG), Summit, N.J.
The Institute of Cancer Research, Sutton, U.K.
Johnson & Johnson, (NYSE:JNJ), New Brunswick, N.J.
MannKind Corp. (NASDAQ:MNKD), Valencia, Calif.
Ruga Corp., Palo Alto, Calif.
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan